Evaluation of serum neurofilament light chain, GFAP, and peripherin as biomarkers in hereditary transthyretin amyloidosis.

Intissar Anan, Gabriella Johannson, Björn Pilebro, Jonas Wixner, Victoria Heldestad, Sandra Arvidsson, Malin Olsson

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Intissar AnanDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0003-2874-7643

Gabriella JohannsonDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Björn PilebroDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0002-4963-3971

Jonas WixnerDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0002-1536-1277

Victoria HeldestadDepartment of Clinical Microbiology, Umea University, Umeå, Sweden.ORCID http://orcid.org/0000-0003-3391-3271

Sandra ArvidssonDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0009-0001-1972-4071

Malin OlssonDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. malin.olsson@umu.se.ORCID http://orcid.org/0000-0002-5300-6487

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early diagnosis and accurate monitoring of disease progression are crucial for timely therapeutic intervention in hereditary transthyretin amyloidosis (ATTRv). Neurofilament light chain (NfL) has emerged as a sensitive biomarker of neuroaxonal injury across neurodegenerative disorders. This study aimed to investigate serum levels of NfL, glial fibrillary acidic protein (GFAP), and peripherin (PRPH) in patients with ATTRV30M amyloidosis and pre-symptomatic gene carriers, compared with controls. Serum samples from 34 ATTRV30M patients, 17 pre-symptomatic ATTRV30M carriers, and 35 controls were analysed using conventional commercially available ELISA platforms to quantify NfL, GFAP, and PRPH concentrations. Serum NfL (sNfL) levels were significantly elevated in ATTRV30M patients compared with controls (threefold, p = 0.0005) and were 1.6-fold higher than in pre-symptomatic ATTRV30M carriers. No significant differences were observed between pre-symptomatic carriers and controls. sNfL concentrations were higher in patients with polyneuropathy disability (PND) score > I compared with PND I (p = 0.0007). Serum GFAP and PRPH levels did not differ significantly among the study groups. Serum NfL represents a promising non-invasive biomarker for assessment of early symptomatic disease and monitoring of disease progression in ATTRV30M amyloidosis. In contrast, sGFAP and sPRPH appear to have limited diagnostic utility in this context.

Indexed as

Amyloid Neuropathies, FamilialGlial Fibrillary Acidic ProteinNeurofilament ProteinsPeripherinsAdultAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament ProteinsPeripherinsPRPH protein, humanAmyloidosisBiomarkerNeurofilament light chainNeuropathyTransthyretin

Identifiers

PMID42259879

DOI10.1038/s41598-026-56777-y

PMCPMC13247259

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.